Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,050Revenue (TTM) $M167Net Margin (%)-98.9Altman Z-Score-4.1
Enterprise Value $M2,044EPS (TTM) $-1.2Operating Margin %-65.8Piotroski F-Score2
P/E(ttm)--Beneish M-Score1.6Pre-tax Margin (%)-98.6Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio3.6Cash flow > EarningsY
Price/Sales10.95-y EBITDA Growth Rate %-19.4Current Ratio3.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-35.5Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M153ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NKTR

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

NKTR is held by these investors:

NKTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Doberstein Stephen KSVP & Chief Scientific Officer 2017-02-16Sell1,261$13.142.05view
Thomsen Jillian B.SVP & Chief Accounting Officer 2017-02-16Sell1,965$13.142.05view
ROBIN HOWARD WPresident & CEO 2017-02-16Sell8,636$13.142.05view
Nicholson JohnSVP & COO 2017-02-16Sell3,237$13.142.05view
Labrucherie Gil MSVP & CFO 2017-02-16Sell2,359$13.142.05view
Hora ManinderSVP Pharma Dev & Mfg Ops 2017-02-16Sell2,195$13.142.05view
Gergel Ivan P.SVP & Chief Medical Officer 2017-02-16Sell1,457$13.142.05view
ROBIN HOWARD WPresident & CEO 2017-02-08Sell87,500$13.042.84view
Nicholson JohnSVP & COO 2017-02-03Sell75,000$12.398.23view
ROBIN HOWARD WPresident & CEO 2017-01-17Sell87,500$12.358.58view

Quarterly/Annual Reports about NKTR:

News about NKTR:

Articles On GuruFocus.com
Weekly CEO Sales Highlight: Monolithic Power Systems, Five Prime Therapeutics, Nektar Therapeutics Feb 15 2016 
Weekly CEO Sells Highlight: Cadence Design Systems Inc., Nektar Therapeutics Inc., Netflix Inc., Pho Sep 27 2015 
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 

More From Other Websites
2:28 am Nektar Therapeutics reports Phase 1 dose-escalation study of single-agent NKTR-214... Feb 21 2017
Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal... Feb 18 2017
Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma Jan 25 2017
Benzinga's Option Alert Recap From January 23 Jan 23 2017
NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Other Events Jan 10 2017
Nektar Therapeutics – Value Analysis (NASDAQ:NKTR) : January 6, 2017 Jan 06 2017
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan... Jan 05 2017
Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : January 5,... Jan 05 2017
ETFs with exposure to Nektar Therapeutics : December 27, 2016 Dec 27 2016
Shire Announces FDA Approval of Adynovate® for use in Children and Surgical Settings Dec 27 2016
ETFs with exposure to Nektar Therapeutics : December 16, 2016 Dec 16 2016
These small-cap stocks are expected to rise at least 31% in 2017 Dec 09 2016
ETFs with exposure to Nektar Therapeutics : December 6, 2016 Dec 06 2016
Is The New York Times Co (NYT) A Good Stock To Buy? Nov 28 2016
ETFs with exposure to Nektar Therapeutics : November 14, 2016 Nov 14 2016
Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London Nov 14 2016
NEKTAR THERAPEUTICS Financials Nov 11 2016
Nektar Therapeutics :NKTR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Nov 10 2016
Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of... Nov 09 2016
NEKTAR THERAPEUTICS Files SEC form 8-K, Other Events Nov 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)